Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 104 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Sclerosis (MS) - Relapsing-remitting Clear all

Conditions: Multiple Sclerosis
Interventions: Blood Draw; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab (Tysabri); Drug
Lead sponsor: Cornerstone Health Care, PA; Other
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Patchogue, New York • High Point, North Carolina • Portland, Oregon

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: MSDX Complex-1 Biomarker test; Other
Lead sponsor: MSDx, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046), Copaxone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 2,244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 57
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 52 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Methotrexate, IV methylprednisolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Ofatumumab, Disease modifying treatment (DMT); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Cullman, Alabama • Chandler, Arizona + 34 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B; Other
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo; Drug
Lead sponsor: Synthon BV; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 794 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Clinically Isolated Syndrome, Radiologically Isolated Syndrome, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Neurologic Autoimmune Disease, Neurologic Disorder, Healthy Aging
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2041
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2025
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Vatelizumab; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Cullman, Alabama • Fort Collins, Colorado • Ormond Beach, Florida + 3 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Sharon Lynch, MD; Other
Eligibility: 18 Years to 60 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Livingston, New Jersey • Portland, Oregon • Richland, Washington + 2 more

Conditions: Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions: Autologous mesenchymal stem cell transplantation; Biological
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Tovaxin Autologous T cell vaccine, Placebo; Biological
Lead sponsor: Opexa Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 33
States / cities: Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 29 more

Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: fingolimod, glatiramer acetate; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,064 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 101
States / cities: Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 88 more

Conditions: Relapsing Remitting MS, Secondary Progressive MS, Primary Progressive MS
Interventions: Caprylic Triglyceride, Placebo; Dietary Supplement
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 59 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Multiple Sclerosis
Interventions: Natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Adrenocorticotropic Hormone; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
Interventions: Remibrutinib (Open Label); Drug
Lead sponsor: Moein Amin; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: abatacept, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 20
States / cities: Phonix, Arizona • Berkeley, California • Los Angeles, California + 17 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: IFN-β-1a (Rebif®); Drug
Lead sponsor: Waukesha Memorial Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Waukesha, Wisconsin

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Interferon beta 1-a, glatiramer acetate, placebo; Drug · Other
Lead sponsor: Fred Lublin; Other
Eligibility: 18 Years to 60 Years
Enrollment: 1,008 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 67
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more

Search by objective public record fields.

Gene Expression Profiles in Multiple Sclerosis (MS)

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

AVONEX® Combination Trial - "ACT"

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Adherence Trial With MS LifeLines ® Services

Efficacy and Safety of GTR in Comparison to Copaxone®

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

MS-ResearchBiomarkerS

Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms

Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839

Cognitive Effects of Immunomodulatory Drugs in MS

Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab

Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS

Autologous T Cell Vaccine (TCV) for Multiple Sclerosis

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Effects of Acthar on Recovery From Cognitive Relapses in MS

A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx